This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Will a Trade War With China Wreak Havoc in US Healthcare?
by Nitish Marwah
It is a known fact that Chinese investments breathe life into small and mid-scale healthcare companies in America.
Dow 30 Stock Roundup: Nike, Walgreens Earnings Impress
by Swarup Gupta
The Dow endured a turbulent week, marked by lingering trade tensions.
Pain, Durect Plunge as FDA Committee Votes Against Remoxy ER
by Zacks Equity Research
Pain Therapeutics (PTIE) plunges as the FDA Advisory Committee votes against the approval of its lead candidate, Remoxy ER.
Achieve Life Sciences' Shares Rise on Positive Clinical Data
by Zacks Equity Research
Achieve Life Sciences' (ACHV) pipeline candidate, cytisine, evaluated for smoking cessation, shows no significant interaction with other medication.
Merck's Keytruda Under FDA Review for Advanced Melanoma
by Zacks Equity Research
Merck (MRK) announces acceptance of its sBLA for Keytruda by the FDA for the treatment of patients with high-risk stage III melanoma.
Pfizer's Breast Cancer Drug Misses Overall Survival in Study
by Zacks Equity Research
Pfizer (PFE) announces that in the phase III PALOMA-3 study, the combination of Ibrance and Faslodex failed to improve overall survival in women with breast cancer compared with Faslodex and placebo.
Lilly Wins Favorable Ruling From U.S. Court in Alimta Row
by Zacks Equity Research
Lilly (LLY) gets a favorable ruling from a U.S. district court in a patent related dispute against Dr. Reddy's Laboratories, concerning its key cancer drug Alimta's vitamin regimen patent.
Pharma Stock Roundup: PTCT Unveils Promising Data, RHHBY to Acquire Rest of FMI
by Zacks Equity Research
Roche (RHHBY) will buy the remaining stake in Foundation Medicine for $2.4 billion. PTC Therapeutics (PTCT) presents encouraging preliminary data from an early-stage study in spinal muscular atrophy.
Zacks Value Trader Highlights: General Electric, Starbucks, Pfizer and ExxonMobil
by Zacks Equity Research
Zacks Value Trader Highlights: General Electric, Starbucks, Pfizer and ExxonMobil
DMD Research Veers Toward Gene Therapy: 3 Stocks in Focus
by Indrajit Bandyopadhyay
Investor focus is on the DMD segment this week with Sarepta presenting encouraging gene therapy study data and the FDA lifting its clinical hold on Solid Biosciences' gene therapy study.
How Long Should You Own a Stock?
by Tracey Ryniec
These 4 criteria can guide investors through the investing maze.
Amgen Gets EU Nod to Add Survival Data on Blincyto's Label
by Zacks Equity Research
Amgen (AMGN) gets approval from the European Commission to add overall survival (OS) data from the TOWER study on the label of its leukemia drug, Blincyto.
Sarepta's Stock Soars on Encouraging Gene Therapy Results
by Zacks Equity Research
Sarepta (SRPT) shares skyrocket on better-than-expected results from an early-stage study, evaluating its gene therapy as a treatment for DMD patients.
Myriad Genetics Wins FDA SPMA Nod for BRACAnalysis CDx
by Zacks Equity Research
The FDA accepts Myriad Genetics' (MYGN) supplementary premarket approval (sPMA) application for BRACAnalysis CDx to identify the best responders to Pfizer's PARP inhibitor, talazoparib.
Glaxo Two-Drug HIV Combo Meets Primary Endpoint in Phase III
by Zacks Equity Research
Glaxo's (GSK) two late-stage studies testing its two-drug HIV regimen of dolutegravir (Tivicay) and lamivudine showed non-inferiority to a standard three-drug regimen
Sarepta Inks Manufacturing Deal for Gene Therapy Program
by Zacks Equity Research
Sarepta (SRPT) strikes manufacturing partnership with Brammer Bio to support its gene therapy development.
Merck's (MRK) Keytruda Gets FDA Approval for Cervical Cancer
by Zacks Equity Research
Merck's (MRK) Keytruda receives accelerated approval for the treatment of patients with advanced cervical cancer.
Alzheimer's Research Stumbles Again: What's the Road Ahead?
by Kinjel Shah
The discontinuation of Lilly/AstraZeneca's two late-stage studies on their Alzheimer's disease candidate, lanabecestat adds to a long list of failed treatment options for this deadly brain disease.
JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space
by Indrajit Bandyopadhyay
Given the growing interest in JAK-inhibitor based treatments, here's a look at some companies that are looking to change the ways to treat autoimmune diseases.
The Zacks Analyst Blog Highlights: Pfizer, Union Pacific, Broadcom, KeyCorp and Ulta Beauty
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Union Pacific, Broadcom, KeyCorp and Ulta Beauty
Biogen Inks Deal With TMS To Acquire Phase II Stroke Asset
by Zacks Equity Research
Biogen (BIIB) signs a definitive option agreement to buy TMS-007, a phase II candidate, for the treatment of acute ischemic stroke (AIS) from private biotech TMS Co., Ltd.
Pharma Stock Roundup: MRK Impresses at ASCO, LLY Gets FDA Nod for Olumiant
by Zacks Equity Research
Merck (MRK) steals the limelight at ASCO with a key lung cancer data presentation. Lilly (LLY) gains FDA nod for the lower dose of its rheumatoid arthritis candidate, Olumiant.
Top Stock Reports for Pfizer, Union Pacific & Broadcom
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Pfizer (PFE), Union Pacific (UNP) and Broadcom (AVGO).
Pfizer Boosts Venture Capital Efforts, Neuroscience in Focus
by Zacks Equity Research
Pfizer (PFE) to pour $600 million in its venture capital arm. About 150 million will be earmarked for companies involved in promising early-stage neuroscience research.
Abbvie's (ABBV) Upadacitinib Fifth RA Study Data Positive
by Zacks Equity Research
AbbVie (ABBV) announces positive top-line results from the fifth phase III study on its JAK inhibitor, upadacitinib in moderate-to-severe rheumatoid arthritis.